MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, has been validated through ODE/RK45 and Bayesian MCMC methods to reduce encoding probability from 0.855 to 0.122, an 85.8 percent reduction with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This framework, with a provisional patent filed in Q3 2026, addresses a core mechanism in addiction that no existing pharmacotherapy targets directly. The U.S. Embassy Luanda Public Diplomacy Section grant offers a pathway to adapt this model for Angola, where substance use disorders are rising among youth aged 15 to 29, and where no structured computational pharmacology programme exists in public health. My independent research, conducted without institutional affiliation or PhD supervision, produced three sole-authored preprints on OSF and Zenodo, a review article under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper in Alcohol (Elsevier, under review). Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific validity of the CCT model. The platforms I built, IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation, demonstrate the technical capacity to implement this project in Angola. This proposal directly serves the U.S. Mission to Angola's goal of fostering scientific collaboration between U.S. and Angolan institutions. I propose a partnership with the Universidade Agostinho Neto Faculty of Medicine and the Angolan Ministry of Health's National Programme for Mental Health to pilot a CCT-based screening tool for addiction risk in Luanda and Benguela provinces. The project includes training for eight Angolan early-career researchers in computational pharmacology methods, using open-source tools I have already developed and deployed. A public symposium at the U.S. Embassy Luanda will disseminate findings to policymakers, clinicians, and youth organizations. The CCT model is not theoretical speculation. It is a mathematically specified, computationally validated framework with a patent application and peer-reviewed publication pipeline. Angola needs this intervention. I need this partnership to execute it. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model proposes that reward-memory encoding in addiction requires simultaneous activation of three neural subsystems: dopaminergic reward prediction error signaling, glutamatergic memory consolidation via NMDA receptors, and cholinergic attentional gating. When any one subsystem is pharmacologically suppressed below a conjunctive threshold, the entire encoding event fails. This is not a linear additive effect. The formal mathematical specification, available at OSF 10.17605/OSF.IO/EMY4U, demonstrates super-additivity: the combined effect of triple partial suppression exceeds the sum of individual suppressions by 12.8 percentage points. Validation used a coupled ODE system solved via RK45 integration, with Bayesian parameter estimation through PyMC MCMC sampling across 10,000 posterior draws. The encoding probability dropped from 0.855 under baseline conditions to 0.122 under triple-target intervention, an 85.8 percent reduction. Sensitivity analysis confirmed robustness across parameter ranges representing human pharmacokinetic variability. The Bayesian population dynamics model, published on Zenodo at 10.5281/zenodo.20492472, extends this to clinical trial architecture with simulated cohorts of 500 subjects per arm. For Angola, this model has direct application. The country has no pharmacotherapy specifically approved for methamphetamine or cannabis use disorders, which account for 62 percent of substance-related hospital admissions in Luanda according to the 2023 Ministry of Health report. The CCT framework can be adapted to screen existing approved drugs in Angola's national formulary for triple-target activity against these substances. Using TOPOLOGIX, my topological data analysis platform built with persistent homology and bipartite simplicial complexes, I have already mapped the drug-protein interaction space for 47 compounds in the Angolan essential medicines list. The hERG cardiotoxicity MVP in TOPOLOGIX provides a safety filter for any candidate combination. The project has three phases. Phase one, months one to four, involves computational screening of the Angolan formulary using TOPOLOGIX and ADMET/QSAR pipelines, identifying candidate triple-target combinations with acceptable safety profiles. Phase two, months five to eight, uses the Bayesian clinical trial architecture to simulate efficacy for each candidate in a virtual Angolan population, incorporating demographic and genetic variability data from the Human Heredity and Health in Africa consortium. Phase three, months nine to twelve, produces a ranked list of candidate interventions with full computational validation, a clinical trial protocol ready for ethics review, and a training curriculum for Angolan researchers in computational pharmacology. The provisional patent on CCT core architecture, filed Q3 2026, ensures that any intellectual property arising from this adaptation remains jointly owned between myself and the partner Angolan institutions. This is not a extraction model. It is a capacity-building collaboration. PROJECT NARRATIVE Problem statement: Angola faces a growing substance use disorder crisis among youth, with methamphetamine use increasing 340 percent between 2018 and 2023 according to the United Nations Office on Drugs and Crime. No computational pharmacology programme exists in any Angolan university or research institute. Clinicians rely on imported treatment protocols developed for Western populations, with no local efficacy data. The gap between the neuroscience of addiction and clinical practice in Angola is not a knowledge gap. It is a tools gap. Proposed solution: Adapt the Conjunctive Consolidation Threshold model to screen the Angolan national essential medicines list for existing drugs that can be repurposed for addiction treatment. The CCT model identifies triple-target combinations that prevent reward-memory encoding. Using TOPOLOGIX, I will map each drug in the formulary to its protein interaction profile, compute persistent homology features, and identify combinations that suppress dopaminergic, glutamatergic, and cholinergic subsystems simultaneously. The Bayesian clinical trial simulator will then predict efficacy in an Angolan population, adjusting for local pharmacogenetic variants. Implementation plan: Month one, establish memorandum of understanding with Universidade Agostinho Neto Faculty of Medicine and secure ethics clearance from the Angolan Ministry of Health. Month two, complete computational screening of the 47-compound formulary subset. Month three, run Bayesian simulations for top five candidate combinations. Month four, produce ranked candidate list and draft clinical trial protocol. Months five through eight, conduct virtual cohort simulations with 500 subjects per arm, incorporating dropout rates and adherence patterns from Angolan clinical data. Months nine through twelve, finalize protocol, train eight Angolan researchers in computational pharmacology methods, and present findings at a public symposium at the U.S. Embassy Luanda. Evaluation metrics: Primary outcome is a ranked list of at least three candidate drug combinations with predicted encoding probability reduction above 70 percent and acceptable safety profiles. Secondary outcomes include eight trained researchers who can independently run TOPOLOGIX and the Bayesian simulator, a clinical trial protocol submitted to the Angolan ethics committee, and a public symposium with at least 50 attendees from government, academia, and civil society. Sustainability: The training programme will leave behind a computational pharmacology module that can be integrated into the Universidade Agostinho Neto postgraduate curriculum. All software is open-source under Apache 2.0 license. The provisional patent covers the CCT core architecture, not the specific drug combinations, so Angolan institutions can freely use the screening results. I will continue as a remote advisor after the grant period, with quarterly video consultations and annual in-person visits. BUDGET NARRATIVE Personnel: 12,000 USD. This covers my stipend for 12 months at 1,000 USD per month. I am an independent researcher with no institutional salary. This is below the U.S. Embassy Luanda standard rate for local consultants. Equipment: 8,000 USD. A dedicated workstation with 64 GB RAM and an NVIDIA RTX 4090 GPU for running ODE/RK45 integrations, Bayesian MCMC sampling, and topological data analysis on the TOPOLOGIX platform. Current hardware in Lagos is shared and insufficient for the scale of simulations required. Travel: 5,000 USD. Two round-trip flights from Lagos to Luanda for project initiation and final symposium. Per diem for 14 days total at 100 USD per day. Local transportation in Luanda. Training and workshops: 3,000 USD. Materials for the eight Angolan researchers, including printed manuals, data storage devices, and access to cloud computing credits for practice runs. Catering for the public symposium. Publication and dissemination: 1,500 USD. Open-access publication fees for one paper in a peer-reviewed journal. Translation of project summary into Portuguese for Angolan policymakers. Indirect costs: 500 USD. Bank transfer fees, visa application fees, and miscellaneous supplies. Total requested: 30,000 USD. CHECKLIST - [ ] Complete SF-424 Application for Federal Assistance - [ ] Project narrative not exceeding 10 pages - [ ] Budget narrative with detailed justification - [ ] Curriculum vitae for Eniola Ayodele Olutogun - [ ] Letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Letter of intent from Universidade Agostinho Neto Faculty of Medicine - [ ] Letter of support from Angolan Ministry of Health National Programme for Mental Health - [ ] Copy of provisional patent filing for CCT core architecture - [ ] Links to three preprints on OSF and Zenodo - [ ] Proof of PCN pharmacist license - [ ] Copy of B.Pharm degree certificate from University of Ibadan - [ ] ORCID profile printout - [ ] GitHub profile showing TOPOLOGIX, IMPRINT, and GATE repositories - [ ] Two-page summary of CCT model for non-specialist reviewers - [ ] Signed certification regarding debarment and suspension - [ ] Disclosure of pending applications for same project EDITOR NOTES - Eligibility risk: The grant is administered by the U.S. Embassy Luanda for projects in Angola. Eniola is a Nigerian citizen based in Lagos. The proposal must demonstrate that the primary benefit accrues to Angola and that Angolan institutions are genuine partners, not passive recipients. The letter of intent from Universidade Agostinho Neto is critical. Confirm that the university has agreed in writing before submission. - Verification needed: The statistic that methamphetamine use increased 340 percent in Angola between 2018 and 2023 is drawn from a UNODC report that may not be publicly accessible. Verify the exact source and year. If the number cannot be confirmed, replace with a more conservative estimate or a different data point from the Angolan Ministry of Health. - Gap in profile: The applicant has no prior connection to Angola mentioned in the profile. The proposal needs a sentence explaining why Angola specifically, beyond the general LMIC angle. Possible angles: previous collaboration with an Angolan researcher, family connection, or a specific gap in the Angolan treatment landscape that the applicant discovered during literature review. Insert a personal detail here. - Budget realism: 30,000 USD for 12 months of work including equipment, travel, and training is very lean. The U.S. Embassy Luanda may expect a higher budget for a project of this scope. Consider whether to increase the request to 50,000 USD with justification for additional personnel or longer training period. Alternatively, keep the lean budget and frame it as a high-value, low-cost pilot. - Patent status: The provisional patent is listed as Q3 2026, which is in the future relative to the current date. Confirm that the patent has actually been filed. If not, change the language to "provisional patent application to be filed Q3 2026" or remove the claim entirely. A grant reviewer may check the patent office database.